Moderna posts Q4 earnings and revenues that topped analysts’ estimates, according to a report by Moderna on Thursday.

  • The biotechnology company reported revenue of $7.21 billion during the period, surpassing Wall Street’s estimates.
  • Moderna reported $4.9 billion in net income for Q4. The company made sales of $17.7B of its Covid-19 vaccine in 2022, distributing 807 million vaccine doses globally. Moderna’s revenue amounted to $18.5 billion for 2021.
  • The company’s 2022 outlook for vaccine sales was $2 billion higher than its prior projection. Moderna initially stated it expected $17 billion in vaccine sales this year.
  • Moderna is conducting a clinical trial for a booster shot that targets the Omicron Covid-19 variant. Moderna stated that it will not request the FDA to expand eligibility to 6-to-11-year-olds until the drug regulator approves the shot for teenagers.

The biotechnology company expects to release clinical trial data on its vaccine for 2-to-5 year-olds sometime in March. MRNA down -4.88%, Pre-market trading.